SynthesisOncotarget2017
Long non-coding RNA NEAT1 overexpression is associated with poor prognosis in cancer patients: a systematic review and meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- The prognostic value of abnormally expressed lncRNAs in prostatic carcinoma: A systematic review and meta-analysis.Medicine · 2017Pooled it
- The Value of lncRNA NEAT1 as a Prognostic Factor for Survival of Cancer Outcome: A Meta-Analysis.Scientific reports · 2017Pooled it
- High expression of long non-coding RNA NEAT1 indicates poor prognosis of human cancer.Oncotarget · 2017Pooled it
- Differential expression of NEAT1 and miR-506-3p in triple-negative breast cancer: potential tissue-based diagnostic biomarkers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The Oncogenic Role of Long Non-Coding RNABiology · 2026Review
- Biomolecular condensates in lung cancer: from molecular mechanisms to therapeutic targeting.Cell death discovery · 2025Review
- The structure, folding kinetics, and dynamics of long poly(UG) RNA.Nucleic acids research · 2025Article
- Non-coding RNAs, a double-edged sword in breast cancer prognosis.Cancer cell international · 2025Review
- Isoform balance of the long noncoding RNA NEAT1 is regulated by the RNA-binding protein QKI, governs the glioma transcriptome, and impacts cell migration.The Journal of biological chemistry · 2024Article
- Molecular Mechanisms of Tumorgenesis and Metastasis of Long Non-coding RNA (lncRNA) NEAT1 in Human Solid Tumors; An Update.Cell biochemistry and biophysics · 2024Review
- RNA: The Unsuspected Conductor in the Orchestra of Macromolecular Crowding.Chemical reviews · 2024Review
- Article
- Review
- Regulatory Role of Fatty Acid Metabolism-Related Long Noncoding RNA in Prostate Cancer: A Computational Biology Study Analysis.Journal of oncology · 2023Article
- Long non-coding RNAeLife · 2022Article
- The Long and the Short of It:Cancers · 2022Review
- Noncoding RNome as Enabling Biomarkers for Precision Health.International journal of molecular sciences · 2022Review
- Comprehensive analysis of autophagy related long non-coding RNAs in prognosis, immunity, and treatment of muscular invasive bladder cancer.Scientific reports · 2022Article
- Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer.British journal of cancer · 2022Review
- Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLong non-coding RNAs (lncRNAs) are playing important roles in cancer progression and metastasis. Recent studies have demonstrated that the lncRNA, nuclear paraspeckle assembly transcript 1 (NEAT1), was aberrantly up-regulated in various types of cancers and was reported to be associated with unfavorable prognosis in cancer patients. This study examined the relationship between NEAT1 and relevant clinical outcomes.
resultsA total of 1354 patients from 11 eligible studies were included in the meta-analysis. The results showed that high expression level of NEAT1 was significantly associated with shorter overall survival in cancer patients (hazard ratio (HR) = 1.53, 95% confidence interval (CI) = 1.36-1.71); in the subgroup analysis, the positive association was also found in patients with hepato-gastroenterol cancers (HR = 1.79, 95% CI = 1.48-2.16), non-small cell lung cancer (HR = 1.35, 95% CI = 1.04-1.76), ovarian cancer (HR = 1.41, 95% CI = 1.11-1.79) and other types of cancers (HR = 1.42, 95% CI = 1.11-1.81). The clinicopathological parameters analysis further showed that increased expression level of NEAT1 was positively correlated with larger tumor size (odds ratio (OR) = 1.74, 95% CI = 1.26-2.41), lymph node metastasis (OR = 2.29, 95% CI = 1.71-3.06), advanced TNM stage (OR = 3.60, 95% CI = 2.27-5.72), poor tumor differentiation (OR = 2.16, 95% CI = 1.58-2.93), distant metastasis (OR = 3.51, 95% CI = 1.75-7.01), and invasion depth (OR = 1.94, 95% CI = 1.36-2.75). MATERIALS AND
methodsA comprehensive search was performed in Pubmed, Embase, Web of Science and CNKI databases, and eligible studies were included based on defined exclusion and inclusion criteria to perform meta-analysis.
conclusionsThe meta-analysis results from present study suggested that increased expression level of NEAT1 was associated with unfavorable prognosis and may serve as a predictive factor for clinicopathological features in various cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.